FDA Approves New Label Indications for Zoetis' Simparica Trio®, Simparica® Chewables, and Revolution® Plus

Zoetis, a global leader in animal health, has announced FDA approval for expanded label indications on three of its flagship parasiticide products: Simparica Trio®, Simparica® Chewables, and Revolution® Plus. These updates reflect the company's commitment to advancing veterinary care and providing innovative solutions for pet health.

Expanded Coverage for Dogs: Simparica Trio and Simparica Chewables

Simparica Trio® and Simparica® Chewables now include the treatment and control of infestations with the Asian longhorned tick (Haemaphysalis longicornis) in dogs. This label extension applies to:

• Simparica Trio®: For dogs eight weeks and older weighing 2.8 pounds or greater.

• Simparica® Chewables: For dogs six months and older weighing 2.8 pounds or greater.

With this approval, Simparica Trio offers the broadest tick coverage in its class, addressing six tick species, including the Asian longhorned tick. This positions the product as the leading combination parasiticide for dogs, having treated over 13 million dogs since its 2020 launch.

“Ticks pose significant health risks to pets,” said Dr. Mason Reichard, Field Parasitologist at Zoetis. “This expanded claim for Simparica Trio equips veterinarians with a powerful tool against the invasive Asian longhorned tick, offering dog owners greater peace of mind.”

Enhanced Protection for Cats: Revolution Plus

The new label indication for Revolution Plus® targets the prevention of Dipylidium caninum (tapeworm) infections by killing Ctenocephalides felis (vector fleas) at the source. This applies to cats and kittens aged eight weeks or older and weighing 2.8 pounds or greater.

With this addition, Revolution Plus stands out as the only feline combination preventative indicated to prevent flea tapeworm infections at the source, further solidifying its reputation as the most-prescribed parasiticide for cats.

Leading Innovation in Parasiticides

These label expansions underscore Zoetis’ dedication to delivering next-generation parasiticide products.

• Simparica Trio® continues to provide all-in-one monthly protection against heartworms, fleas, ticks, and intestinal parasites.

• Revolution Plus® now offers comprehensive protection against a range of parasites, including fleas, ticks, ear mites, and roundworms, while preventing flea tapeworm infections at the source.

Safety Information

Zoetis emphasizes the importance of following safety guidelines for these products:

• Simparica Trio®: Use with caution in dogs with a history of seizures. Adverse reactions may include vomiting and diarrhea.

• Simparica®: Not for dogs under six months of age. May cause neurologic signs such as tremors or unsteadiness.

• Revolution Plus®: Use cautiously in cats with neurologic disorders. Side effects may include lethargy and anorexia.

Full prescribing information is available at SimparicaTrioPI.com, SimparicaPI.com, and RevolutionPlusPI.com.